Treatment of ADHD: Guanfacine Extended Release in ADHD

Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR, <4 mg/d) adjunctive to a long-acting psychostimulant for ADHD continued in 461 subjects.

Bibliographic Details
Main Authors: J Gordon Millichap, John J Millichap
Format: Article
Language:English
Published: Pediatric Neurology Briefs Publishers 2014-08-01
Series:Pediatric Neurology Briefs
Subjects:
Online Access:https://www.pediatricneurologybriefs.com/articles/129